RIVM is among the top 4 of institutes in the area of environment and health research that collaborate most frequently in EU projects, as was demonstrated by a 2017 study for the European Commission. Our experts and researchers are involved in a wide range of international projects. On this page we present an overview of these projects.

Horizon 2020

The Horizon 2020 programme of the European Commission is of key importance for the funding of RIVM's international collaboration. Horizon 2020 succeeds the Seventh Framework Programme and is the biggest EU Research and Innovation programme in Europe. Horizon 2020 stimulates research and innovation in the EU. The Horizon 2020 work programme comprises of several pillars and various thematic sections. RIVM is mainly involved in projects within the societal challenges, but our institute is also involved in projects in other pillars. Within the Societal Challenges RIVM focuses mainly on Health, Climate Action and Environment, Secure Societies, and Food Security. 

Horizon 2020 projects

COMPARE 

NanoFASE 

NanoReg2

BLUEHEALTH

EuroMix 

VIROGENESIS 

INHERIT 

One Health EJP

LANDMARK 

SUSTAIN 

PROMISS 

HBM4EU EJP

I-MOVE +

CONCERT 

CALIBRATE 

SOPHIE

INSPIRATION PRISMA FAIRWAY GRACIOUS
nTRACK PATROLS SEAFOODTOMORROW REFINE
VERIFY PROMETROFOOD    

 

Third Health Programme projects

EMERGE 

Completed

FP7

Together with partners all over Europe, RIVM was involved in over 70 projects funded by the 7th Framework Programme for Research and Technological Development, FP7. This EU programme ran from 2007 until 2013 and awarded grants to co-finance research, technological development and demonstration projects. Grants ware determined on the basis of calls for proposals and a peer review process. RIVM is still in progress on several projects.
 

FP7 projects

PREPARE 

ADVance 

NCC-Foam 

ANTIDotE 

Optimunise 

 

Completed

IMI

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA. IMI launches research and/or training projects every year. Project participants are recruited through open and competitive calls for research proposals. The selection of the winning proposals is based on independent peer review. RIVM is a partner in several IMI financed projects.

Innovative Medicines Initiative 

PERISCOPE 

Vac2Vac 

RESCEU  

 

Other Projects

EMETNET CleaR
Completed  

Joint Actions

Basicly, a Joint Action is a group of coherent activities on a specific topic, which is jointly funded by the European Commission and the EU Member States who have decided to participate in it. Joint Actions have a clear EU added value and are co-financed either by competent authorities that are responsible for health in the Member States or in the third countries participating in the Programme, or by public sector bodies and non-governmental bodies mandated by those competent authorities. As a result, a Joint Action also provides outcomes that offer benefits on the national level. 

Joint Actions

CHRODIS Plus